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Several reports suggest that the canonical nuclear factor-kappaB (NF-kB) pathway is constitutively activated in a subset of prostate
cancer cells. However, except for RelA (p65), little is known about the status of NF-kB transcription factors in prostate cancer tissues.
To clarify the status of NF-kB subunits, we analysed the expression and subcellular localisation of RelA, RelB, c-Rel, p50, and p52 on
tissue array sections containing respectively 344, 346, 369, 343, and 344 cores from 75 patients. The subcellular localisation of NF-kB
factors was tested against relevant clinical parameters (preoperative prostate-specific antigen, pathological stage, and postoperative
Gleason grade). With the exception of c-Rel, each subunit was detected in the nucleus of cancer cells: significant nuclear expression
of RelB, RelA, p52, and p50 was seen in 26.6, 15.6, 10.7, and 10.5% of cores, respectively. Surprisingly, cores expressing both nuclear
RelA and p50 canonical pathway proteins were less frequently observed than cores expressing other subunit combinations such as
RelB–p52 and RelA–RelB. In addition, the nuclear localisation of RelB correlated with patient’s Gleason scores (Spearman
correlation: 0.167; P¼0.018). The nuclear localisation of both canonical and noncanonical NF-kB subunits in prostate cancer cells
suggests for the first time that different NF-kB pathways and dimers may be activated in the progression of the disease.
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In Caucasian men, prostate cancer is the most frequently
diagnosed cancer and a leading cause of cancer death. Presently,
the majority of clinically localised tumours are detected early and
treated aggressively even though some early-stage tumours can
remain latent and may not require aggressive therapy. New
prognostic tools are needed to distinguish between low- and high-
risk tumours in order to tailor treatment strategies. Understanding
the molecular mechanisms of prostate cancer progression will
undoubtedly lead to the development of new molecular prognostic
markers.
The nuclear factor-kappaB (NF-kB) transcription factor family
is composed of five structurally related members that possess
an N-terminal Rel homology (RH) domain involved in protein–
protein interactions and DNA binding (Ghosh and Karin, 2002).
The NF-kB proteins can be divided into two classes based on
sequences C-terminal to their RH domain. The class 1 includes Rel
(c-Rel), RelA (p65), and RelB proteins that are characterised by a
C-terminal transactivation domain. NF-kB1 (p50 and its precursor
p105) and NF-kB2 (p52 and its precursor p100) form the second
class; p105 and p100 contain inhibitory C-terminal ankyrin repeats
that are cleaved to create transcriptionally active p50 and p52
proteins. Rel/NF-kB proteins exist as homo- and heterodimers.
The best-studied dimers include the canonical (RelA/p50) and
noncanonical (RelB/p52) NF-kB complexes. Normally, the activa-
tion of NF-kB requires signals that converge to IkB kinases (IKKs).
In the canonical pathway, the IKK complex (IKKa, b, g)
phosphorylates IkBs, which are then ubiquitinated and targeted
for proteasome-dependent degradation. In the noncanonical
pathway, IKKa regulates the processing of the p100 precursor.
As a result of the activation of either pathway, NF-kB dimers
translocate to the nucleus and activate the expression of various
genes involved in cell growth, differentiation, inflammatory
responses, and the regulation of apoptosis (Aggarwal, 2004).
The NF-kB pathways and genes are frequently altered in
lymphoid and nonlymphoid cancers (Rayet and Gelinas, 1999).
For instance, chromosomal alterations involving the c-Rel and
NF-kB2 genes have been detected in several B- and T-cell lympho-
mas (Liptay et al, 1997; Munzert et al, 2000). It has been shown
that constitutively nuclear and active RelA/p50 dimers can prevent
cell death by apoptosis in many cancer cell types after chemo-
therapy, radiotherapy, or TNF-a treatment (Barkett and Gilmore,
1999; Baldwin, 2001) and have also been detected in the nuclei of
pancreatic and breast carcinomas (Sovak et al, 1997; Wang et al,
1999). More recently, constitutive activation of NF-kB (RelA/p50)
has been detected in androgen-independent prostate cancer cell
lines as well as in prostate cancer tissues (Chen and Sawyers, 2002;
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sGasparian et al, 2002; Suh et al, 2002; Ayala et al, 2004; Ross et al,
2004; Shukla et al, 2004; Sweeney et al, 2004) and appears to
promote cell growth, survival, and metastasis (Huang et al, 2001;
Hodge et al, 2003; Levine et al, 2003; Ling et al, 2003). In
particular, we and others have shown that nuclear localisation of
RelA in primary prostate tumours is linked to poor clinical
outcomes (Lessard et al, 2003; Ayala et al, 2004; Fradet et al, 2004;
Ismail et al, 2004; Ross et al, 2004).
While RelA has become a candidate prognostic marker of
prostate cancer progression, little is known about the expression
and the subcellular localisation of other NF-kB subunits. The
present study provides the first large-scale immunohistochemical
characterisation of all NF-kB transcription factors in tissue-
arrayed prostate cancer specimens. Our results show that all
NF-kB subunits are expressed in prostate tissues and that except
for c-Rel, they are often detected in the nucleus of cancer cells.
Interestingly, nuclear RelA and p50 are less frequently detected in
the same cores than all other subunit combinations. In addition,
the number of nuclear RelB-positive cores increased significantly
with increasing Gleason scores. These results suggest that most
NF-kB transcription factors, especially noncanonical subunits,
may play a role in the progression of prostate cancer.
MATERIALS AND METHODS
Prostate tissue microarray preparation
Archival formalin-fixed, paraffin-embedded (FFPE) human pros-
tate tumour specimens were used to construct a human prostate
tissue array of benign, high-grade prostatic intraepithelial
neoplasia (PIN), and cancer (adenocarcinoma) tissue samples.
The array was subdivided into normal, PIN, low Gleason (2, 2/3, 3),
and high Gleason (3/4, 4, 4/5, 5) cores. Benign tissue cores were
obtained from transition zone biopsies of radical prostatectomy
specimens. Core tissue prostatectomy specimens (0.6mm dia-
meter) were obtained from preselected regions of individual
paraffin-embedded donor blocks and precisely arrayed into a new
recipient paraffin block with a tissue arrayer (Beecher Instrument,
Silver Spring, MD, USA). After the block construction was
completed, 5mm sections were cut with a microtome using an
adhesive-coated tape sectioning system (Instrumedics, Hackensack,
NJ, USA) to support the adhesion of the array elements.
Immunohistochemical staining
Tissue sections were immunostained for NF-kB transcription
factors using the biotin–streptavidin immunoperoxidase method
as previously described (Fradet et al, 2004). Briefly, FFPE
tissue array slides were initially deparaffinised with toluene and
rehydrated through graded ethanol. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide for 10min. An
antigen retrieval technique was applied by boiling slides for 10min
at 951C in a 0.01 M sodium citrate buffer, pH 6.0. The staining of
c-Rel was enhanced using 1mM EDTA (pH 8.0) instead of citrate.
Tissue sections were incubated with a protein blocking serum-free
reagent (Dako Diagnostics, Mississauga, ON, Canada) for 15min to
block nonspecific binding. The NF-kB subunit expression was
studied using mouse monoclonal NF-kB RelA (p65) F-6, rabbit
polyclonal RelB C-19, mouse monoclonal c-Rel B6, rabbit
polyclonal NF-kB p50 NLS (all from Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and mouse monoclonal NF-kB p52 (Upstate
Biotechnology, Lake Placid, NY, USA). Primary antibodies were
applied at a concentration of 1:10 (c-Rel) or 1:50 (RelA, RelB,
p50, p52) in PBS and were incubated for 2h at room temperature.
Immune complexes were revealed using a biotin-conjugated
broad-spectrum secondary antibody (20min), then streptavidin-
peroxidase conjugate for 20min (DakoCytomation, Mississauga,
ON, Canada), followed by chromogen (0.06% 3,3-diaminobenzi-
dine tetrahydrochloride, 0.01% hydrogen peroxide in PBS) for
5min. Sections were counterstained with Mayer’s haematoxylin,
dehydrated, and then mounted. Negative controls were performed
by omitting the primary antibody.
Analysis
Damaged or nonrepresentative tissue cores (e.g., absence of
epithelial tissue) were excluded from the analysis, leaving 344
(RelA), 346 (RelB), 369 (c-Rel), 343 (p52), and 344 (p50) cores
from 75 patients. Cores were scored either as positive (1) or
negative (0) for unequivocal brown nuclear NF-kB staining in at
least 5% of cancer cells. Clinical data were also available in a subset
of samples in which preoperative serum prostate-specific antigen
(pPSA), pathologic Gleason score (sum), and pathologic stage were
available for 41, 47, and 46 patients, respectively. All statistical
tests were performed using SPSS, version 10 (SPSS, Chicago, IL,
USA).
RESULTS
Nuclear factor-kappaB subunit expression and subcellular
localisation in prostatic tissues
As shown in Figure 1, all NF-kB subunits were expressed in
prostatic tissues. Most benign glands were characterised by
a strong cytoplasmic staining of the basal cell constituent and
a variable cytoplasmic staining of the secretory (luminal) cells.
Nuclear factor-kB nuclear expression was usually not detected
in benign tissues with the exception of a few cores in which RelB
(two out of 40) and p52 (one out of 39) were localised in the
nucleus of secretory cells. Prostatic intraepithelial neoplasia
samples expressed weak to strong cytoplasmic levels of NF-kB
subunits and only one core (one out of 23) demonstrated RelA
nuclear staining. Finally, all NF-kB proteins were present in the
cytoplasm of cancer cells and all except c-Rel were detected in the
nuclei of cancer tissues at variable frequencies. Table 1 compares
the frequencies of NF-kB nuclear staining between normal, PIN,
and cancer specimens. In all cases, the frequency of positive cores
was significantly higher in cancer tissues as compared to non-
cancerous tissues. Within cancer specimens, nuclear RelB expres-
sion was the most commonly detected followed by RelA, p52, and
p50. When cancer tissues were divided into low- to intermediate-
grade (Gleason scores 2, 2/3, 3) and high-grade (Gleason scores
3/4, 4, 4/5, 5) tumours, no statistically significant difference was
observed between the two groups, but there was a trend towards
increased RelB nuclear staining in high-grade specimens (Table 2).
Nuclear detection of several NF-jB subunits in individual
cores
The NF-kB proteins function as homo- and heterodimers. To
assess the relative importance of these dimers in prostatic tissues,
we calculated the proportion of cores in which both subunits of an
NF-kB heterodimer were detected in the nucleus of prostatic cells
(Figure 2). Importantly, although all subunit combinations were
observed in cancer cores, the canonical RelA–p50 pair was less
frequently detected than other subunit pairs. In particular, the
proportion of cores positive for both RelA and RelB (class 1
subunits) was significantly higher than that of cores positive for
RelA and p50 (P¼0.008).
Relationship between nuclear NF-jB and clinical
parameters in prostate cancer patients
We performed statistical analyses to identify possible correlations
and/or associations between NF-kB nuclear staining and pPSA
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significant relationship was obtained between nuclear NF-kB and
pPSA or pathological stage. In contrast, the number of nuclear
RelB-positive cores increased significantly with increasing Gleason
scores (Spearman coefficient: 0.167; P¼0.018; Table 3).
DISCUSSION
Although prostate cancer can be detected in its early stages, it is
still difficult to predict whether it will remain latent or progress to
an advanced, metastatic disease. This is largely due to the lack of
Figure 1 Immunohistochemical detection of c-Rel (A–C), RelA (D–F), p50 (G–I), RelB (J–L), and p52 (M–O) in normal, PIN, and cancerous
prostate tissues ( 400). Note nuclear RelB staining in a subset of normal glands (J). Also note a mixture of weak and strong p52 cytoplasmic staining in
normal glands (M). Enlargements are provided to more clearly distinguish the subcellular localisation in cancer specimens.
Table 1 Nuclear localisation of NF-kB transcription factors in prostatic tissue cores
RelA p50 RelB p52
Tissue type N
No.
positive (%) PN
No.
positive (%) PN
No.
positive (%) PN
No.
positive (%) P
Normal 39 0 (0) 37 0 (0) 40 2 (5.0) 39 1 (2.6)
PIN 23 1 (4.3) 21 0 (0) 24 0 (0) 24 0 (0)
Cancer 282 44 (15.6) 0.001 285 30 (10.5) 0.004 282 75 (26.6) o0.001 281 30 (10.7) 0.025
w
2 was used to test the association of nuclear NF-kB expression with tissue type (cancer vs noncancer). P-value less than 0.05 was considered as significant. NF-kB¼nuclear
factor-kB; PIN¼prostatic intraepithelial neoplasia.
Table 2 Nuclear localisation of NF-kB transcription factors in low to intermediate (2, 2/3, 3) and high (3/4, 4, 4/5, 5) Gleason grade scores
RelA p50 RelB p52
Gleason group N
No.
positive (%) PN
No.
positive (%) PN
No.
positive (%) PN
No.
positive (%) P
Low 170 24 (14.1) 174 16 (9.2) 169 40 (23.7) 167 16 (9.6)
High 112 20 (17.9) 0.405 111 14 (12.6) 0.431 113 35 (31.0) 0.104 114 14 (12.3) 0.555
w
2 was used to test the association between nuclear NF-kB and tissue grade. P-value less than 0.05 was considered as significant. NF-kB¼nuclear factor-kB.
NF-jB in prostate cancer
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sclinically proven molecular markers of prostate cancer progres-
sion. There are hundreds of candidate genes and proteins under
investigation but few have been validated in multivariate analyses
(Tricoli et al, 2004). We and others have recently shown that
RelA, a member of the NF-kB transcription factor family, is an
independent predictor of biochemical recurrence (Ayala et al,
2004; Fradet et al, 2004; Ross et al, 2004). In addition, we have
detected high levels of nuclear RelA staining in lymph node
metastases and in patients who developed bone metastases
(Lessard et al, 2003; Ismail et al, 2004). Hence, RelA appears to
play a role in the progression of prostate cancer but little is known
about the status of other NF-kB family members, and no
simultaneous analysis of the subcellular localisation of these
subunits has been previously reported in prostate tissues.
In the present study, we characterised the expression and the
subcellular localisation of RelA, p50, RelB, p52, and c-Rel. All
subunits are expressed in prostatic tissues, and all but c-Rel can
be detected in the nucleus of prostatic cells, more frequently in
cancerous tissues. This suggests that both canonical (RelA, p50) and
the noncanonical (e.g., RelB, p52) NF-kB subunits can be activated
in prostate cancer cells, whereas c-Rel remains inactive. Notably, a
recent study reported a negative or nonspecific p50 expression in
prostate tumours (Shukla et al, 2004). Conversely, we observed
high levels of cytoplasmic p50 expression in cancer tissues. This
discrepancy may be related to use of different antibodies.
The NF-kB subunits can potentially form six heterodimers:
RelA/p50, RelB/p52, RelA/p52, RelB/p50, RelA/RelB, and p50/p52.
Importantly, each dimer may differently affect the cellular
transcriptome, thus influencing disease progression. While in this
study we did not directly assess the presence of specific
heterodimers in prostate cancer specimens, our results provide
an indication of those subunits present in the nucleus of cancer
cells. Our results clearly demonstrate that within a given sample,
we were more likely to find nuclear RelA and RelB, while the
nuclear localisation of RelA and p50 was less frequently observed.
If these subunits are relocalised within the same cell, this would
suggest that noncanonical dimers are more frequently activated in
prostate cancer, which is in contrast with the more usually
observed activation of the canonical pathway in other cancers.
Since RelA–RelB dimers are not regulated by IkB proteins, they
may act together or in concert with other transcription factors to
attract histone acetyl transferases and cofactors and constitutively
drive the transcription of specific genes. On the other hand, it has
been reported that RelB forms transcriptionally inactive complexes
with RelA in mouse embryonic fibroblasts (Marienfeld et al, 2003).
In this model, RelB sequesters RelA and thereby represses RelA-
dependent transcription. Whether RelA–RelB complexes exist in
prostate cancer cells remains to be elucidated, but our results
justify further investigation.
There is also a possibility that the RelB–p52 combination is more
frequent than the canonical RelA–p50 pair (Figure 2). Given that
RelB and p52 have been shown to be activated in other tumour types
such as B- and T-cell lymphomas as well as in breast carcinoma
(Dejardin et al, 1998; Rayet and Gelinas, 1999; Cogswell et al, 2000),
they may also play a role in prostate cancer development and
progression. Interestingly, both nuclear RelB and nuclear p52 were
also detected in a subset of benign tissues (Table 1). However, it is
important to note that all benign tissues collected were from
cancerous prostates. Consequently, the nuclear localisation of RelB
and p52 may evoke a normal transient activation, but may also
reflect a cellular response to the tumour environment or a transi-
tional state towards transformation. To test this hypothesis, we are
presently characterising the activation status of NF-kB subunits in
cancer-free prostate specimens obtained from young male autopsies.
Correlation analyses between NF-kB subunits and relevant
clinical parameters revealed a significant relationship between
RelB nuclear expression and patient’s Gleason score (Table 3).
Similarly, there was also a trend towards higher RelB nuclear
staining in high-grade cancer tissue cores (Table 2). Whether RelB
or other subunits confer a more aggressive phenotype to prostatic
carcinoma remains to be determined. To this end, we are presently
expanding the analysis to more clearly define the role of RelB in
prostate cancer progression.
The absence of a correlation between RelA nuclear expression
and patient’s Gleason score confirms our previous observations
(Lessard et al, 2003). Despite this, RelA acts as an independent
predictor of patient’s outcome (Fradet et al, 2004), which suggests
that p50 and p52 should also be analysed to assess their potential
as prognostic markers.
To our knowledge, this is the first large-scale immunohisto-
chemical characterisation of NF-kB transcription factors in the
same cohort of prostate cancer patients. Our results not only
provide further evidence for a role of the canonical NF-kB pathway
in prostate cancer, but also suggest a potential role for other
NF-kB subunits and pathways. Studies are ongoing to validate
the usefulness of specific NF-kB subunits, or combinations, as
prognostic markers.
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Figure 2 Frequencies of NF-kB subunit combinations in the prostate
cancer cores. The vertical pattern is for the canonical RelA–p50 pair.
Noncanonical combinations are represented as follows: the diagonal
pattern is for other class 1/class 2 dimers, and the dashed pattern is for class
1/class 1 or class 2/class 2 dimers. **Po0.01 w
2 between RelA–p50 and
RelA–RelB.
Table 3 Correlation between NF-kB nuclear localisation and patient’s
Gleason scores
Subunits Coefficient P-value
RelA 0.078 0.272
p50  0.018 0.803
RelB 0.167 0.018*
p52  0.019 0.793
Spearman’s s coefficient was used to test the relationship between nuclear NF-kB
expression and Gleason scores. *P-value less than 0.05 was considered as significant.
NF-kB¼nuclear factor-kB.
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